Free Trial

King Luther Capital Management Corp Trims Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Charles River Laboratories International logo with Medical background

Key Points

  • King Luther Capital Management Corp reduced its stake in Charles River Laboratories International by 13.3%, now owning 45,398 shares valued at approximately $6.83 million.
  • Charles River Laboratories reported a quarterly EPS of $3.12, exceeding analyst expectations of $2.50, with revenues of $1.03 billion for the quarter.
  • Institutional investors control nearly 99% of the company's stock, with significant recent investments from firms like D1 Capital Partners and Assenagon Asset Management.
  • Need better tools to track Charles River Laboratories International? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

King Luther Capital Management Corp lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 13.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 45,398 shares of the medical research company's stock after selling 6,945 shares during the period. King Luther Capital Management Corp owned about 0.09% of Charles River Laboratories International worth $6,833,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Two Sigma Securities LLC grew its stake in Charles River Laboratories International by 4.3% in the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock worth $366,000 after acquiring an additional 81 shares in the last quarter. Wahed Invest LLC grew its stake in Charles River Laboratories International by 6.5% in the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock worth $244,000 after acquiring an additional 81 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its stake in Charles River Laboratories International by 2.7% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company's stock worth $589,000 after acquiring an additional 102 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Charles River Laboratories International by 2.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock worth $763,000 after acquiring an additional 105 shares in the last quarter. Finally, Veracity Capital LLC grew its stake in Charles River Laboratories International by 3.4% in the 1st quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company's stock worth $496,000 after acquiring an additional 107 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 400 shares of Charles River Laboratories International stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $150.04, for a total transaction of $60,016.00. Following the completion of the sale, the executive vice president directly owned 24,916 shares in the company, valued at approximately $3,738,396.64. The trade was a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Up 1.5%

CRL traded up $2.23 during trading on Wednesday, hitting $154.98. The stock had a trading volume of 2,208,959 shares, compared to its average volume of 999,150. The company has a market capitalization of $7.63 billion, a PE ratio of -116.53, a PEG ratio of 4.87 and a beta of 1.48. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $230.02. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The stock has a 50 day simple moving average of $156.34 and a two-hundred day simple moving average of $149.06.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. During the same period in the previous year, the firm posted $2.80 earnings per share. The business's revenue for the quarter was up .6% compared to the same quarter last year. On average, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Barclays upped their target price on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 7th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a research note on Wednesday, May 14th. Finally, Wall Street Zen upgraded shares of Charles River Laboratories International from a "hold" rating to a "strong-buy" rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $175.69.

View Our Latest Stock Report on Charles River Laboratories International

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Articles

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Should You Invest $1,000 in Charles River Laboratories International Right Now?

Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines